title: [Current status of combination therapies of angiogenesis inhibitors: vascular normalization activity of a novel angiogenesis inhibitor E7820].
authors.forename: Taro
authors.initials: T
authors.lastname: Semba
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005346:Fibroblast Growth Factors; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000494:pharmacology; D039421:Integrin alpha2; D051379:Mice; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy*; D013449:Sulfonamides / Q000008:administration & dosage / Q000494:pharmacology; D042461:Vascular Endothelial Growth Factor A
chemical_list: D020533:Angiogenesis Inhibitors; D007211:Indoles; D039421:Integrin alpha2; D013449:Sulfonamides; D042461:Vascular Endothelial Growth Factor A; C468872:N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzene-sulfonamide; D005346:Fibroblast Growth Factors